Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib.

carboplatin - Generic mfg.

Lynparza (olaparib) - Merck (MSD), AstraZeneca

eprenetapopt (APR-246) - Aprea

http://www.ncbi.nlm.nih.gov/pubmed/42003968

Begoña Pineda; Elena Obrador; J Alejandro Pérez-Fidalgo; Javier Perea; Juan Jose Martinez-Pretel; María Rodrigo-Faus; Martín Pérez-Leal; Paloma Sánchez-Serrano; Stergios Boussios

Apr 21, 2026